Viatris And Biocon Line Up EU Bevacizumab
As Accord Receives Positive CHMP Opinion For Abiraterone
Viatris’ Mylan has received a positive opinion from the EMA’s CHMP for its bevacizumab biosimilar rival to Avastin under two different names. Meanwhile, Accord has received an endorsement for a generic version of Zytiga.
